Private Management Group Inc. Has $36.54 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Private Management Group Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 451,040 shares of the biopharmaceutical company’s stock after selling 1,671 shares during the quarter. Gilead Sciences accounts for 1.4% of Private Management Group Inc.’s holdings, making the stock its 15th biggest holding. Private Management Group Inc.’s holdings in Gilead Sciences were worth $36,539,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of GILD. South Dakota Investment Council boosted its stake in Gilead Sciences by 3.3% in the fourth quarter. South Dakota Investment Council now owns 222,411 shares of the biopharmaceutical company’s stock valued at $18,018,000 after buying an additional 7,025 shares in the last quarter. NewSquare Capital LLC boosted its stake in Gilead Sciences by 2.4% in the fourth quarter. NewSquare Capital LLC now owns 53,336 shares of the biopharmaceutical company’s stock valued at $4,264,000 after buying an additional 1,247 shares in the last quarter. Cutter & CO Brokerage Inc. boosted its stake in Gilead Sciences by 4.5% in the fourth quarter. Cutter & CO Brokerage Inc. now owns 4,173 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 180 shares in the last quarter. GAMMA Investing LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at about $525,000. Finally, Linden Thomas Advisory Services LLC boosted its stake in Gilead Sciences by 6.7% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 34,134 shares of the biopharmaceutical company’s stock valued at $2,765,000 after buying an additional 2,153 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 0.1 %

GILD stock traded up $0.08 during mid-day trading on Tuesday, reaching $67.03. The company’s stock had a trading volume of 5,239,545 shares, compared to its average volume of 7,302,715. The company has a market cap of $83.46 billion, a price-to-earnings ratio of 14.90, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. The business’s 50 day moving average price is $71.68 and its 200 day moving average price is $76.46. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12 month low of $65.90 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.67 earnings per share. On average, equities research analysts predict that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.59%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 68.44%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Barclays reduced their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. Wells Fargo & Company cut their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Mizuho cut their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, StockNews.com lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $84.71.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.